Supercede Therapeutics, Inc., a startup biotech company focused on small molecule drug development, today announced preclinical efficacy data from its lead therapeutic program to treat obesity.

Merck’s phase 3 HYPERION study of Winrevair meets primary endpoint in recently diagnosed adults with pulmonary arterial hypertension: Rahway, New Jersey Tuesday, June 24, 2025, ...

Topline results were announced from a phase 3 study evaluating sotatercept-csrk in recently diagnosed adults with pulmonary arterial hypertension (PAH).

Panelists discuss how riociguat targets the nitric oxide pathway and is approved for both Group 1 PAH and Group 4 chronic ...

Follistatin-344 peptide has garnered significant attention in scientific research due to its intricate interactions with ...

Follistatin-344 (FS-344), a glycoprotein variant, has emerged as a focal point in scientific research due to its potential ...

The ZENITH study found that in high-risk PAH, add-on sotatercept was tied to lower risk for death from any cause, lung ...

After a major shareholder pushed back, Keros is returning half of its capital to investors in a move that Guggenheim analysts ...

KER-065 is designed to act as a ligand trap and inhibit the biological effects of myostatin and activin A, two ligands that signal through activin receptors, to increase skeletal muscle regeneration, ...

In muscle tissue, Activin interacts with the Activin RII receptor, triggering intracellular signaling pathways. Activin RII phosphorylates Activin RI, which activates the Smad2/3 signaling pathway.